Reduced Toll-Like Receptor 9 Expression on Peripheral C D14 + Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy
Antiviral Therapy2013Vol. 19(7), pp. 637–643
Citations Over TimeTop 19% of 2013 papers
Yi‐Wen Huang, Cheng-Kai Hsu, Shih‐Chang Lin, Shu‐Chen Wei, Jui-Ting Hu, Han-Yu Chang, Cher‐Wei Liang, Ding‐Shinn Chen, Pei‐Jer Chen, Ping‐Ning Hsu, Sien-Sing Yang, Jia‐Horng Kao
Abstract
CHB patients display reduced TLR9 expression on peripheral CD14+ monocytes, which is independent of host and viral markers, and on liver tissue. Responders to pegylated interferon and those under entecavir demonstrate restoration of TLR9 expression. On-treatment TLR9 expression on peripheral monocytes might predict response to pegylated interferon therapy.
Related Papers
- → Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment(2015)73 cited
- → Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa(2022)1 cited
- Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.(2015)
- [HBsAg SEROCONVERSION IN THE TREATMENT OF CHRONIC HEPATITIS B WITH PEGYLATED INTERFERON].(2019)
- → O‐044: Low serum HBsAg and HBV DNA levels identify strongest responders of pegylated interferon addition to entecavir in HBeAg positive chronic hepatitis B(2018)